Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Abstract EN

We analyze the impact of cyclosporine (CsA) levels in the development of acute graft-versus-host disease (aGVHD) after reduced intensity conditioning allogeneic hematopoietic transplantation (allo-RIC).

We retrospectively evaluated 156 consecutive patients who underwent HLA-identical sibling allo-RIC at our institution.

CsA median blood levels in the 1st, 2nd, 3rd and 4th weeks after allo-RIC were 134 (range: 10–444), 219 (54–656), 253 (53–910) and 224 (30–699) ng/mL; 60%, 16%, 11% and 17% of the patients had median CsA blood levels below 150 ng/mL during these weeks.

53 patients developed grade 2–4 aGVHD for a cumulative incidence of 45% (95% CI 34–50%) at a median of 42 days.

Low CsA levels on the 3rd week and sex-mismatch were associated with the development of GVHD.

Risk factors for 1-year NRM and OS were advanced disease status (HR: 2.2, P = 0.02 ) and development of grade 2–4 aGVHD (HR: 2.5, P < 0.01 ), while there was a trend for higher NRM in patients with a low median CsA concentration on the 3rd week ( P = 0.06 ).

These results emphasize the relevance of sustaining adequate levels of blood CsA by close monitoring and dose adjustments, particularly when engraftment becomes evident.

CsA adequate management will impact on long-term outcomes in the allo-RIC setting.